Piramal Pharma Limited share price
NSE: PPLPHARMA · ISIN INE0DK501011
Key numbers
- Market cap
- ₹ 27,867 Cr
- Current price
- ₹ 210.31
- 52-week high / low
- ₹ 232 / 132
- Stock P/E
- -
- Book value
- ₹ 61.5
- Dividend yield
- 0.07%
- ROCE
- 1.2%
- ROE
- -4.0%
- Debt to equity
- 0.70
- Sales growth (3 yrs)
- 7.6%
- Profit growth (3 yrs)
- -
- 1-year return
- 7.1%
About Piramal Pharma Limited
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing; offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs, and other generic and speciality products; and analgesics, skin care, vitamin and mineral supplement, kids' wellness, digestives, and women's health, as well as geriatric care. In addition, the company operates as a contract development and manufacturing organization, providing process development, scale-up, and GMP manufacturing services for vaccines and biologics. The company was incorporated in 2020 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2,754 | 1,934 | 2,140 | 2,752 | 2,270 |
| Operating profit | 561 | 107 | 196 | 461 | 195 |
| Net profit | 154 | -82 | -136 | -9 | -69 |
| EPS (₹) | 1.16 | -0.62 | -1.03 | -0.07 | -0.52 |
Investor presentation summary (2026-07-29)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Revenue from Operations 2,270 1,934 17%
- PAT (before exceptional item) (69) (102) 32%
Guidance & outlook
- Particulars Q1FY27 Q1FY26 % Change
- Kenalog®: Progressing on integration activities. Expect supplies to start from Q2FY27.
Growth & demand
- Broad-based growth across India and overseas sites, supported by healthy order inflows and
- Power Brands: Grew 23% year-on-year and contributed 53% of Consumer Healthcare sales.
Margins & costs
- Improved Operating Performance: Higher capacity utilization, operating leverage, pricing discipline
- excellence drove EBITDA margin expansion across most sites despite inflationary pressures.
Capex & expansion
- and operational excellence supported EBITDA margin expansion.
- margin expansion. Our CDMO business delivered broad -based growth across India and overseas sites,
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.